Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

NCT04096950 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Spinal Cord Injury

Interventions

BIOLOGICAL: MT-3921 Low dose

Sponsor

Tanabe Pharma America, Inc.